Amarin Corp Plc (AMRN)

[Sam81]

Jefferies Link;

Interesting and well detailed coverage with conservative price target of $3.50 and assuming positive reduce it and Vascepa showing a benefit on final analysis in early '18, the upside could be $14/sh. as they estimate total peak potential risk-adjusted sales of ~$1.0 billion by 2030 comprising of $391 million in sales from severe hypertriglyceridemia (unadjusted) and $627 million from mixed dyslipidemia (75% risk-discount)....ie very conservative numbers.

At this time, they only model U.S. revenues for Vascepa and do not include ex-U.S. sales estimates, including China where AMRN has recently entered into an agreement with Eddingpharm. China alone could represent a significant opportunity, and at this time represents upside to our valuation.

Good read, enjoy !!!

https://drive.google.com/file/d/0B1gB2YESBJV7eTJ0YlBUaExUZmc/view?usp=sharing